|
1
|
Kaplan GG and Windsor JW: The four
epidemiological stages in the global evolution of inflammatory
bowel disease. Nat Rev Gastroenterol Hepatol. 18:56–66. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ramos GP and Papadakis KA: Mechanisms of
disease: Inflammatory bowel diseases. Mayo Clin Proc. 94:155–165.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Vergnolle N: Protease inhibition as new
therapeutic strategy for GI diseases. Gut. 65:1215–1224. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huang S, Fu Y, Xu B, Liu C, Wang Q, Luo S,
Nong F, Wang X, Huang S, Chen J, et al: Wogonoside alleviates
colitis by improving intestinal epithelial barrier function via the
MLCK/pMLC2 pathway. Phytomedicine. 68:1531792020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clayburgh DR, Shen L and Turner JR: A
porous defense: The leaky epithelial barrier in intestinal disease.
Lab Invest. 84:282–291. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li K, Marano C, Zhang H, Yang F, Sandborn
WJ, Sands BE, Feagan BG, Rubin DT, Peyrin-Biroulet L, Friedman JR
and De Hertogh G: Relationship between combined histologic and
endoscopic endpoints and efficacy of ustekinumab treatment in
patients with ulcerative colitis. Gastroenterology. 159:2052–2064.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ungaro R, Colombel JF, Lissoos T and
Peyrin-Biroulet L: A treat-to-target update in ulcerative colitis:
A systematic review. Am J Gastroenterol. 114:874–883. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rubin DT, Ananthakrishnan AN, Siegel CA,
Sauer BG and Long MD: ACG clinical guideline: Ulcerative colitis in
adults. Am J Gastroenterol. 114:384–413. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Khare V, Krnjic A, Frick A, Gmainer C,
Asboth M, Jimenez K, Lang M, Baumgartner M, Evstatiev R and Gasche
C: Mesalamine and azathioprine modulate junctional complexes and
restore epithelial barrier function in intestinal inflammation. Sci
Rep. 9:28422019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scarallo L, Bolasco G, Barp J, Bianconi M,
di Paola M, Di Toma M, Naldini S, Paci M, Renzo S, Labriola F, et
al: Anti-tumor necrosis factor-alpha withdrawal in children with
inflammatory bowel disease in endoscopic and histologic remission.
Inflamm Bowel Dis. Apr 9–2021.(Epub ahead of print). PubMed/NCBI
|
|
11
|
Yang H, Zhang L, Weakley SM, Lin PH, Yao Q
and Chen C: Transforming growth factor-beta increases the
expression of vascular smooth muscle cell markers in human
multi-lineage progenitor cells. Med Sci Monit. 17:BR55–BR61. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhu B, Zhai J, Zhu H and Kyprianou N:
Prohibitin regulates TGF-beta induced apoptosis as a downstream
effector of Smad-dependent and -independent signaling. Prostate.
70:17–26. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sinpitaksakul SN, Pimkhaokham A,
Sanchavanakit N and Pavasant P: TGF-beta1 induced MMP-9 expression
in HNSCC cell lines via Smad/MLCK pathway. Biochem Biophys Res
Commun. 371:713–718. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kihara N, de la Fuente SG, Fujino K,
Takahashi T, Pappas TN and Mantyh CR: Vanilloid receptor-1
containing primary sensory neurones mediate dextran sulphate sodium
induced colitis in rats. Gut. 52:713–719. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Scheinin T, Butler DM, Salway F, Scallon B
and Feldmann M: Validation of the interleukin-10 knockout mouse
model of colitis: Antitumour necrosis factor-antibodies suppress
the progression of colitis. Clin Exp Immunol. 133:38–43. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu XC, Mei Q, Xu JM and Hu J: Balsalazine
decreases intestinal mucosal permeability of dextran sulfate
sodium-induced colitis in mice. Acta Pharmacol Sin. 30:987–993.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kannengiesser K, Maaser C, Heidemann J,
Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W and
Kucharzik T: Melanocortin-derived tripeptide KPV has
anti-inflammatory potential in murine models of inflammatory bowel
disease. Inflamm Bowel Dis. 14:324–331. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu X, Xu J, Mei Q, Han L and Huang J:
Myosin light chain kinase inhibitor inhibits dextran sulfate
sodium-induced colitis in mice. Dig Dis Sci. 58:107–114. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arrieta MC, Madsen K, Doyle J and Meddings
J: Reducing small intestinal permeability attenuates colitis in the
IL10 gene-deficient mouse. Gut. 58:41–48. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martini E, Krug SM, Siegmund B, Neurath MF
and Becker C: Mend your fences: The epithelial barrier and its
relationship with mucosal immunity in inflammatory bowel disease.
Cell Mol Gastroenterol Hepatol. 4:33–46. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Buckley A and Turner JR: Cell biology of
tight junction barrier regulation and mucosal disease. Cold Spring
Harb Perspect Biol. 10:a0293142018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Otani T and Furuse M: Tight junction
structure and function revisited: (Trends in cell biology 30,
805–817, 2020). Trends Cell Biol. 30:10142020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rajasekaran AK, Hojo M, Huima T and
Rodriguez-Boulan E: Catenins and zonula occludens-1 form a complex
during early stages in the assembly of tight junctions. J Cell
Biol. 132:451–463. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mohanan V, Nakata T, Desch AN, Lévesque C,
Boroughs A, Guzman G, Cao Z, Creasey E, Yao J, Boucher G, et al:
C1orf106 is a colitis risk gene that regulates stability of
epithelial adherens junctions. Science. 359:1161–1166. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
UK IBD Genetics Consortium, ; Barrett JC,
Lee JC, Lees CW, Prescott NJ, Anderson CA, Phillips A, Wesley E,
Parnell K, Zhang H, et al: Genome-wide association study of
ulcerative colitis identifies three new susceptibility loci,
including the HNF4A region. Nat Genet. 41:1330–1334. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang C, Shu W, Zhou G, Lin J, Chu F, Wu H
and Liu Z: Anti-TNF-α therapy suppresses proinflammatory activities
of mucosal neutrophils in inflammatory bowel disease. Mediators
Inflamm. 2018:30218632018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Olesen CM, Coskun M, Peyrin-Biroulet L and
Nielsen OH: Mechanisms behind efficacy of tumor necrosis factor
inhibitors in inflammatory bowel diseases. Pharmacol Ther.
159:110–119. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Al-Sadi R, Guo S, Ye D, Rawat M and Ma TY:
TNF-α modulation of intestinal tight junction permeability is
mediated by NIK/IKK-α axis activation of the canonical NF-κB
pathway. Am J Pathol. 186:1151–1165. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen S, Zhu J, Chen G, Zuo S, Zhang J,
Chen Z, Wang X, Li J, Liu Y and Wang P: 1,25-Dihydroxyvitamin D3
preserves intestinal epithelial barrier function from TNF-α induced
injury via suppression of NF-kB p65 mediated MLCK-P-MLC signaling
pathway. Biochem Biophys Res Commun. 460:873–878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ye D and Ma TY: Cellular and molecular
mechanisms that mediate basal and tumour necrosis
factor-alpha-induced regulation of myosin light chain kinase gene
activity. J Cell Mol Med. 12:1331–1346. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Blair SA, Kane SV, Clayburgh DR and Turner
JR: Epithelial myosin light chain kinase expression and activity
are upregulated in inflammatory bowel disease. Lab Invest.
86:191–201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Stolfi C, Troncone E, Marafini I and
Monteleone G: Role of TGF-beta and Smad7 in gut inflammation,
fibrosis and cancer. Biomolecules. 11:172020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maul J, Loddenkemper C, Mundt P, Berg E,
Giese T, Stallmach A, Zeitz M and Duchmann R: Peripheral and
intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel
disease. Gastroenterology. 128:1868–1878. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan L, Qi Y, Qu S, Chen X, Li A, Hendi M,
Xu C, Wang L, Hou T, Si J and Chen S: B. adolescentis ameliorates
chronic colitis by regulating Treg/Th2 response and gut microbiota
remodeling. Gut Microbes. 13:1–17. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Ceuninck van Capelle C, Spit M and Ten
Dijke P: Current perspectives on inhibitory SMAD7 in health and
disease. Crit Rev Biochem Mol Biol. 55:691–715. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang S, Fei T, Zhang L, Zhang R, Chen F,
Ning Y, Han Y, Feng XH, Meng A and Chen YG: Smad7 antagonizes
transforming growth factor beta signaling in the nucleus by
interfering with functional Smad-DNA complex formation. Mol Cell
Biol. 27:4488–4499. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fantini MC, Rizzo A, Fina D, Caruso R,
Sarra M, Stolfi C, Becker C, Macdonald TT, Pallone F, Neurath MF
and Monteleone G: Smad7 controls resistance of colitogenic T cells
to regulatory T cell-mediated suppression. Gastroenterology.
136:1308–1316, e1-e3. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Olsen T, Rismo R, Cui G, Goll R,
Christiansen I and Florholmen J: TH1 and TH17 interactions in
untreated inflamed mucosa of inflammatory bowel disease, and their
potential to mediate the inflammation. Cytokine. 56:633–640. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sedda S, Marafini I, Dinallo V, Di Fusco D
and Monteleone G: The TGF-β/Smad system in IBD pathogenesis.
Inflamm Bowel Dis. 21:2921–2925. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vieira EL, Leonel AJ, Sad AP, Beltrão NR,
Costa TF, Ferreira TM, Gomes-Santos AC, Faria AM, Peluzio MC, Cara
DC and Alvarez-Leite JI: Oral administration of sodium butyrate
attenuates inflammation and mucosal lesion in experimental acute
ulcerative colitis. J Nutr Biochem. 23:430–436. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ardizzone S, Bevivino G and Monteleone G:
Mongersen, an oral Smad7 antisense oligonucleotide, in patients
with active Crohn's disease. Therap Adv Gastroenterol. 9:527–532.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Feagan BG, Sands BE, Rossiter G, Li X,
Usiskin K, Zhan X and Colombel JF: Effects of mongersen (GED-0301)
on endoscopic and clinical outcomes in patients with active Crohn's
disease. Gastroenterology. 154:61–64.e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu F, Shao Q, Hu M, Zhao Y, Dong R, Fang
K, Xu L, Zou X, Lu F, Li J and Chen G: Wu-Mei-Wan ameliorates
chronic colitis-associated intestinal fibrosis through inhibiting
fibroblast activation. J Ethnopharmacol. 252:1125802020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zorzi F, Calabrese E, Di Fusco D, De
Cristofaro E, Biancone L, Casella S, Palmieri G and Monteleone G:
High Smad7 in the early post-operative recurrence of Crohn's
disease. J Transl Med. 18:3952020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Izzo R, Bevivino G, De Simone V, Sedda S,
Monteleone I, Marafini I, Di Giovangiulio M, Rizzo A, Franzè E,
Colantoni A, et al: Knockdown of Smad7 with a specific antisense
oligonucleotide attenuates colitis and colitis-driven colonic
fibrosis in mice. Inflamm Bowel Dis. 24:1213–1224. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Monteleone G, Kumberova A, Croft NM,
McKenzie C, Steer HW and MacDonald TT: Blocking Smad7 restores
TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin
Invest. 108:601–609. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Barreiro-de Acosta M, Lorenzo A, Mera J
and Dominguez-Muñoz JE: Mucosal healing and steroid-sparing
associated with infliximab for steroid-dependent ulcerative
colitis. J Crohns Colitis. 3:271–276. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wen FQ, Liu X, Kobayashi T, Abe S, Fang Q,
Kohyama T, Ertl R, Terasaki Y, Manouilova L and Rennard SI:
Interferon-gamma inhibits transforming growth factor-beta
production in human airway epithelial cells by targeting Smads. Am
J Respir Cell Mol Biol. 30:816–822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Schiffer M, von Gersdorff G, Bitzer M,
Susztak K and Böttinger EP: Smad proteins and transforming growth
factor-beta signaling. Kidney Int Suppl. 77:S45–S52. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Monteleone G, Del Vecchio Blanco G,
Monteleone I, Fina D, Caruso R, Gioia V, Ballerini S, Federici G,
Bernardini S, Pallone F and MacDonald TT: Post-transcriptional
regulation of Smad7 in the gut of patients with inflammatory bowel
disease. Gastroenterology. 129:1420–1429. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Troncone E, Marafini I, Stolfi C and
Monteleone G: Involvement of Smad7 in inflammatory diseases of the
gut and colon cancer. Int J Mol Sci. 22:39222021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Latella G: Redox imbalance in intestinal
fibrosis: Beware of the TGFβ-1, ROS, and Nrf2 connection. Dig Dis
Sci. 63:312–320. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Cui Y, Zhu C, Ming Z, Cao J, Yan Y, Zhao
P, Pang G, Deng Z, Yao Y and Chen Q: Molecular mechanisms by which
casein glycomacropeptide maintains internal homeostasis in mice
with experimental ulcerative colitis. PLoS One. 12:e01810752017.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Laudisi F, Dinallo V, Di Fusco D and
Monteleone G: Smad7 and its potential as therapeutic target in
inflammatory bowel diseases. Curr Drug Metab. 17:303–306. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Speca S, Rousseaux C, Dubuquoy C, Rieder
F, Vetuschi A, Sferra R, Giusti I, Bertin B, Dubuquoy L, Gaudio E,
et al: Novel PPARγ modulator GED-0507-34 levo ameliorates
inflammation-driven intestinal fibrosis. Inflamm Bowel Dis.
22:279–292. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Marafini I, Zorzi F, Codazza S, Pallone F
and Monteleone G: TGF-beta signaling manipulation as potential
therapy for IBD. Curr Drug Targets. 14:1400–1404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Yamashita A, Inamine T, Suzuki S, Fukuda
S, Unoike M, Kawafuchi Y, Machida H, Isomoto H, Nakao K and
Tsukamoto K: Genetic variants of SMAD2/3/4/7 are associated with
susceptibility to ulcerative colitis in a Japanese genetic
background. Immunol Lett. 207:64–72. 2019. View Article : Google Scholar : PubMed/NCBI
|
